<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01222234</url>
  </required_header>
  <id_info>
    <org_study_id>11936</org_study_id>
    <nct_id>NCT01222234</nct_id>
  </id_info>
  <brief_title>Impact of Vitamin D Therapies on Chronic Kidney Disease</brief_title>
  <official_title>Impact of Vitamin D Therapies on Monocyte Function in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigation will consist of a prospective study utilizing two separate populations of
      patients with 25(OH)D deficiency, one population with chronic kidney disease (CKD) and one
      with normal renal function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D helps form and strengthens bones by allowing the body to absorb calcium. Vitamin D
      helps the immune system fight infection as well as helps keep muscles strong. Without enough
      vitamin D, bones can become weak, thin and brittle.

      Vitamin D is useful in people with all different types of health issues. CKD is the slow loss
      of kidney function over time. The main function of the kidneys is to remove wastes and excess
      water from the body. This loss of function usually takes months or years to occur Patients
      with CKD often have low levels of vitamin D in their blood.

      This study will have two groups of patients with CKD and one group of patients that have
      normal kidney function, but all groups will have low levels of vitamin D. The two groups with
      CKD (group 1 and group 2) will receive either cholecalciferol or calcitriol. The purpose of
      having a control group (group 3) without CKD will be to evaluate if any changes that are
      witnessed in response to vitamin D therapy are specific to patients with kidney disease or
      apply to all patients with vitamin D deficiency who receive vitamin D supplements.

      There are two different drugs in this study. One is called Calcitriol and is approved by the
      Food and Drug Administration (FDA) as a vitamin D supplement. The other drug is called
      cholecalciferol and it is approved by the FDA. Unlike calcitriol, cholecalciferol is a
      nutritional form of vitamin D that can often be found in various types of foods and its
      chemical structure must be changed by the body to become the active form of vitamin D. It is
      believed that cholecalciferol may have different effects in the body compared to calcitriol.
      It is possible that CKD patients would benefit from receiving both of these drugs, but this
      is currently unclear. While on this study you will receive either one of these study drugs,
      depending on which group you are assigned to.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monocyte Protein Expression</measure>
    <time_frame>8 weeks of therapy</time_frame>
    <description>Flow cytometry analysis of monocyte CD14, ACE, VDR, and Mac-1 expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 24,25(OH)2D Levels in CKD vs. Non-CKD Subjects Receiving Cholecalciferol</measure>
    <time_frame>8 weeks of therapy</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Chronic Kidney Disease (CKD)</condition>
  <condition>End-stage Renal Disease (ESRD)</condition>
  <arm_group>
    <arm_group_label>Group 1: Cholecalciferol - CKD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Calcitriol - CKD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). They will be administered calcitriol 0.25mcg daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Cholecalciferol - non-CKD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm have low vitamin D levels and normal kidney function. They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol - CKD</intervention_name>
    <description>Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks</description>
    <arm_group_label>Group 1: Cholecalciferol - CKD</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Calcitriol - CKD</intervention_name>
    <description>Calcitriol 0.25 mcg once daily for 8 weeks</description>
    <arm_group_label>Group 2: Calcitriol - CKD</arm_group_label>
    <other_name>1,25(OH)2D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol - non-CKD</intervention_name>
    <description>Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks</description>
    <arm_group_label>Group 3: Cholecalciferol - non-CKD</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic kidney disease w/GFR&lt;35ml/min

          -  Nutritional vitamin D deficiency, defined as 25(OH)D &lt; 25ng/ml

          -  Secondary hyperparathyroidism, PTH&gt;75pg/mL

        Exclusion Criteria:

          -  Active infection

          -  Recent hospitalization for acute illness (within last month)

          -  Refusal to study participation

          -  History of chronic inflammatory disease process (i.e. inflammatory bowel, rheumatoid
             arthritis, SLE, etc.)

          -  Allergy to cholecalciferol or calcitriol

          -  History of parathyroidectomy

          -  Functional renal transplant within 5 years

          -  Current treatment with immunosuppressant medications

          -  Noncompliance with prescribed medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Stubbs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <results_first_submitted>November 24, 2015</results_first_submitted>
  <results_first_submitted_qc>April 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2016</results_first_posted>
  <last_update_submitted>April 11, 2016</last_update_submitted>
  <last_update_submitted_qc>April 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Jason Stubbs, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Cholecalciferol</title>
          <description>Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). Patients will be randomized to group 1 or group 2.
Cholecalciferol: Cholecalciferol tablet, 50,000 units twice a week</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Calcitriol</title>
          <description>Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). Patients will be randomized to group 1 or group 2.
calcitriol: calcitriol 0.25 mcg every day</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Cholecalciferol</title>
          <description>Patients in this arm have low vitamin D levels and normal kidney function. They will be put into group 3.
Cholecalciferol: Cholecalciferol tablet, 50,000 units twice a week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Cholecalciferol</title>
          <description>Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). Patients will be randomized to group 1 or group 2.
Cholecalciferol: Cholecalciferol tablet, 50,000 units twice a week</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Calcitriol</title>
          <description>Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). Patients will be randomized to group 1 or group 2.
calcitriol: calcitriol 0.25 mcg every day</description>
        </group>
        <group group_id="B3">
          <title>Group 3: Cholecalciferol</title>
          <description>Patients in this arm have low vitamin D levels and normal kidney function. They will be put into group 3.
Cholecalciferol: Cholecalciferol tablet, 50,000 units twice a week</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.1" spread="13.3"/>
                    <measurement group_id="B2" value="59.8" spread="11.6"/>
                    <measurement group_id="B3" value="48.5" spread="14.2"/>
                    <measurement group_id="B4" value="56.1" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Monocyte Protein Expression</title>
        <description>Flow cytometry analysis of monocyte CD14, ACE, VDR, and Mac-1 expression</description>
        <time_frame>8 weeks of therapy</time_frame>
        <population>The primary comparison for this outcome was between only CKD groups (groups 1 and 2); therefore data from the non-CKD group (group 3) was not analyzed for this outcome. Only 15 patients per group had data analyzed for this outcome of interest; thus, the number analyzed per group differs from the enrolled numbers.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Cholecalciferol - CKD</title>
            <description>Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). Patients will be randomized to group 1 or group 2.
Cholecalciferol 50,000 IU twice weekly for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Calcitriol - CKD</title>
            <description>Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). Patients will be randomized to group 1 or group 2.
Calcitriol 0.25 mcg every day</description>
          </group>
        </group_list>
        <measure>
          <title>Monocyte Protein Expression</title>
          <description>Flow cytometry analysis of monocyte CD14, ACE, VDR, and Mac-1 expression</description>
          <population>The primary comparison for this outcome was between only CKD groups (groups 1 and 2); therefore data from the non-CKD group (group 3) was not analyzed for this outcome. Only 15 patients per group had data analyzed for this outcome of interest; thus, the number analyzed per group differs from the enrolled numbers.</population>
          <units>relative fluorescence units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34110" spread="9372"/>
                    <measurement group_id="O2" value="38540" spread="16880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1359" spread="347.2"/>
                    <measurement group_id="O2" value="1360" spread="290.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VDR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2799" spread="1210"/>
                    <measurement group_id="O2" value="3468" spread="3123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mac-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14318" spread="4196.4"/>
                    <measurement group_id="O2" value="14278.5" spread="4891.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in 24,25(OH)2D Levels in CKD vs. Non-CKD Subjects Receiving Cholecalciferol</title>
        <time_frame>8 weeks of therapy</time_frame>
        <population>The primary comparison for this outcome of interest was between subjects taking cholecalciferol, so the calcitriol group (group 2) was excluded from the analysis. Only 15 patients per group had data analyzed for this outcome of interest; thus, the number analyzed per group differs from the enrolled numbers.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: CKD Cholecalciferol</title>
            <description>Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). Patients will be randomized to group 1 or group 2.
Cholecalciferol: Cholecalciferol tablet, 50,000 units twice a week</description>
          </group>
          <group group_id="O2">
            <title>Group 3: Non-CKD Cholecalciferol</title>
            <description>Patients in this arm have low vitamin D levels and normal kidney function. They will be put into group 3.
Cholecalciferol: Cholecalciferol tablet, 50,000 units twice a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 24,25(OH)2D Levels in CKD vs. Non-CKD Subjects Receiving Cholecalciferol</title>
          <population>The primary comparison for this outcome of interest was between subjects taking cholecalciferol, so the calcitriol group (group 2) was excluded from the analysis. Only 15 patients per group had data analyzed for this outcome of interest; thus, the number analyzed per group differs from the enrolled numbers.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="0.73"/>
                    <measurement group_id="O2" value="3.59" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Cholecalciferol</title>
          <description>Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). Patients will be randomized to group 1 or group 2.
Cholecalciferol: Cholecalciferol tablet, 50,000 units twice a week</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Calcitriol</title>
          <description>Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). Patients will be randomized to group 1 or group 2.
calcitriol: calcitriol 0.25 mcg every day</description>
        </group>
        <group group_id="E3">
          <title>Group 3: Cholecalciferol</title>
          <description>Patients in this arm have low vitamin D levels and normal kidney function. They will be put into group 3.
Cholecalciferol: Cholecalciferol tablet, 50,000 units twice a week</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jason Stubbs</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>913-588-9252</phone>
      <email>jstubbs@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

